<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220530055031N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-06-10</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Investigation of different calcium treatment regimens on patients after thyroidectomy</public_title>
      <acronym></acronym>
      <scientific_title>Comparative Evaluation of the Impact of Routine Calcium intake versus Recommended Calcium Intake in Patients Undergoing Total Thyroidectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-05-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>140</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/76946</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are randomly assigned to one of 2 treatment groups by block randomization method. Block randomization with different block sizes is used for random allocation. Block sizes are multiples of 2. Initially, block sizes are randomly selected. Finally, one of the different permutations is determined for the equal group size. Random numbers are done using Excel. The study will be done blindly. In such a way that the patients do not know the type of supplement received and the drugs are given to the patients in the same packaging without specifying the specifications, and only the researcher knows the type of drug prescribed and the doctor and the person in charge of evaluating the patients who talk to the patient, They do not know the prescribed medicine, Blinding description: With the help of getting random numbers using Excel for each patient. The study will be done blindly. In such a way that the patients do not know the type of supplement received and the drugs are given to the patients in the same packaging without any specifications, and only the researcher knows the type of drug prescribed and the doctor and the person in charge of evaluating the patients who talk to the patient about the type of drug Prescribed do not know.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Hypocalcemia after total thyroidectomy surgery.</hc_freetext>
      <i_freetext>Intervention 1: intervention group: In this group, they will be treated with a high-dose calcium regimen (500 mg calcium carbonate every 8 hours, 0.5 microgram calcitriol 1 tablet every 12 hours, and 500 mg calcifort every 6 hours) after surgery. The calcium level of patients will be checked 12 hours before surgery and 8 hours after surgery, and every 8 hours after surgery, patients will be checked for signs and symptoms of hypocalcemia and serum calcium level. The presence and absence of symptoms are collected in the checklist.   Patients are discharged if there are no hypocalcemic symptoms and normocalcemic serum. Patients will return to the clinic for clinical examinations 5 days after the operation, and the serum calcium level of the patients will be checked again. Intervention 2: Control group: A group of patients received only routine treatment (500 mg of calcium every 8 hours and 1000 units of calcitriol daily) after surgery. The calcium level of patients will be checked 12 hours before surgery and 8 hours after surgery, and every 8 hours after surgery, patients will be checked for signs and symptoms of hypocalcemia and serum calcium level. The presence and absence of symptoms are collected in the checklist.   Patients are discharged if there are no hypocalcemic symptoms and normocalcemic serum. Patients will return to the clinic for clinical examinations 5 days after the operation, and the serum calcium level of the patients will be checked again.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyed Amir Miratashi Yazdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam khomeini ave. sina hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 0000</telephone>
        <email>amiratahi@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Amir Miratashi Yazdi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Imam khomeini ave,. sina hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1136746911</zip>
        <telephone>+98 21 6312 0000</telephone>
        <email>amiratahi@tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Potential early diagnosis of thyroid cancer
total thyroidectomy With or without the spread of cancer to the lateral parts of the neck
Absence of hypercalcemia before surgery or any kind of kidney disorder that causes calcium metabolism disorder
Absence of abnormal preoperative parathyroid hormone levels or concomitant parathyroid diseases
No history of any type of thyroid or neck surgery
Age over 18 years</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pathological diagnosis after surgery except papillary thyroid cancer
Patients who have a history of taking calcium supplements before surgery
History of kidney or urinary tract disease
History of radiation therapy or other tumors</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E83.51</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Hypocalcemia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>intervention group: In this group, they will be treated with a high-dose calcium regimen (500 mg calcium carbonate every 8 hours, 0.5 microgram calcitriol 1 tablet every 12 hours, and 500 mg calcifort every 6 hours) after surgery. The calcium level of patients will be checked 12 hours before surgery and 8 hours after surgery, and every 8 hours after surgery, patients will be checked for signs and symptoms of hypocalcemia and serum calcium level. The presence and absence of symptoms are collected in the checklist.   Patients are discharged if there are no hypocalcemic symptoms and normocalcemic serum. Patients will return to the clinic for clinical examinations 5 days after the operation, and the serum calcium level of the patients will be checked again.</i_keyword>
      <i_keyword>Control group: A group of patients received only routine treatment (500 mg of calcium every 8 hours and 1000 units of calcitriol daily) after surgery. The calcium level of patients will be checked 12 hours before surgery and 8 hours after surgery, and every 8 hours after surgery, patients will be checked for signs and symptoms of hypocalcemia and serum calcium level. The presence and absence of symptoms are collected in the checklist.   Patients are discharged if there are no hypocalcemic symptoms and normocalcemic serum. Patients will return to the clinic for clinical examinations 5 days after the operation, and the serum calcium level of the patients will be checked again.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum calcium level before surgery. Timepoint: The calcium level of patients will be checked 12 hours before surgery and will be collected in the checklist. Method of measurement: The patient's serum calcium level, measured in the laboratory.</prim_outcome>
      <prim_outcome>Serum calcium level after surgery. Timepoint: The calcium level of the patients will be checked every 8 hours after the operation and will be collected in the checklist. Method of measurement: The patient's serum calcium level, measured in the laboratory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Symptoms caused by hypocalcemia. Timepoint: Every 8 hours after the operation, the patients will be checked for signs and symptoms of hypocalcemia and the presence and absence of symptoms will be collected in the checklist. Method of measurement: Expert opinion.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-05-15</approval_date>
        <contact_name>Ethics committee of medical faculty of Tehran University of Medical Sciences</contact_name>
        <contact_address>Room 604, 6th floor, Tehran University of Medical Sciences Central Building, Keshavarz Blvd., Qods St. intersection Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
